Last reviewed · How we verify
NFC-1
At a glance
| Generic name | NFC-1 |
|---|---|
| Also known as | NFC1 |
| Sponsor | Aevi Genomic Medicine, LLC, a Cerecor company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder (PHASE1)
- Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions (PHASE1)
- Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD (PHASE2, PHASE3)
- PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations (PHASE2)
- PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations (PHASE2)
- Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NFC-1 CI brief — competitive landscape report
- NFC-1 updates RSS · CI watch RSS
- Aevi Genomic Medicine, LLC, a Cerecor company portfolio CI